Article
Preliminary study on the mechanism of SAHA in the treatment of refractory epilepsy induced by GABRG2(F343L) mutation.
Biochemical pharmacology - 1 Sept 2024
Wang Jie, Wu Wenwen, Wan Jiali, Zhan Longwu, Chen Yuhan, Yun Feng, Ji Yuhua, Suo Guihai, Zheng Yuqin, Shen Dingding, Zhang Qi
Abstract excerpt
Mutations in the γ-amino butyric acid type A (GABAA) receptor γ2 subunit gene, GABRG2, have been associated with refractory epilepsy. Increasing evidence indicates that suberoylanilide hydroxamic acid (SAHA), a broad-spectrum histone acetyltransferases (HDACs) inhibitor, can inhibit seizure onset. However, the mechanisms involved remains unknown. The present study aimed to explore the anti-epileptic effect and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
